PEG-loxenatide linked to lower kidney risk in type 2 diabetes
A multicenter Chinese cohort found PEG-loxenatide was associated with fewer major renal events in high-risk type 2 diabetes, with mixed cardiovascular results.
Renal disease, dialysis, transplantation and electrolyte disorders.
Renal disease, dialysis, transplantation and electrolyte disorders.